Literature DB >> 8299480

Nocturnal blood glucose control in type I diabetes mellitus.

G B Bolli1, G Perriello, C G Fanelli, P De Feo.   

Abstract

A major problem in replacing insulin in type I diabetes mellitus is that currently no depot preparation exists that is capable of mimicking the background insulin secretion of the healthy pancreas. Because all of the currently available intermediate- or long-acting insulin preparations have a peaked-action profile, excess insulin action at midnight and insulin waning at dawn occur whenever such an insulin preparation is given at supper time. If the target fasting plasma glucose is the ambitious near-normoglycemia of intensive insulin therapy, intermediate-acting insulin at suppertime easily results in hypoglycemia in the early evening hours and hyperglycemia in the fasting state. The problems of overnight glycemia in type I diabetes are further complicated by the dawn phenomenon and the Somogyi phenomenon. The dawn phenomenon is the combination of an initial decrease in insulin requirements between approximately 2400 and approximately 0300, followed by an increase in the insulin needs between approximately 0500 and approximately 0800. The dawn phenomenon is the result of changes in hepatic (and extrahepatic) insulin sensitivity, which are best attributed to nocturnal growth hormone secretion. The dawn phenomenon is a day-to-day reproducible event that occurs in nearly all diabetic patients. Its contribution to fasting hyperglycemia correlates with diabetes duration (inversely) and the HbA1c percentage (directly). Overall, it is estimated that the specific contribution of the dawn phenomenon to fasting hyperglycemia is approximately 2 mM (approximately 35 mg/dl), but it may be much greater because of the warning of the depot-insulin preparation injected the previous evening. The Somogyi phenomenon, strictly speaking, refers to fasting hyperglycemia that occurs after inducement of nocturnal hypoglycemia by regular insulin. Because the present therapeutic regimens of NPH/Lente insulin given at suppertime cause overnight hyperinsulinemia, excessive fasting hyperglycemia rarely follows nocturnal hypoglycemia, except when excessive glucose is ingested to correct hypoglycemia. However, nocturnal hypoglycemia may easily deteriorate glycemic control later in the day, because it induces prolonged posthypoglycemic insulin resistance, which results in postbreakfast and late-morning hyperglycemia. With nocturnal insulin therapy, it is important to consider the problems of insulin pharmacokinetics, the dawn phenomenon, and the Somogyi phenomenon to prevent both nocturnal hypoglycemia and excessive fasting hyperglycemia.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8299480     DOI: 10.2337/diacare.16.3.71

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  18 in total

1.  Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia.

Authors:  S Pampanelli; C Fanelli; C Lalli; M Ciofetta; P D Sindaco; M Lepore; F Modarelli; A M Rambotti; L Epifano; A Di Vincenzo; L Bartocci; B Annibale; P Brunetti; G B Bolli
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

2.  Insulin doses before and one year after pump start: children have a reversed dawn phenomenon.

Authors:  Tom Nicolajsen; Andreas Samuelsson; Ragnar Hanas
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

Review 3.  Advances in diabetes for the millennium: insulin treatment and glucose monitoring.

Authors:  Daniel Einhorn
Journal:  MedGenMed       Date:  2004-09-16

Review 4.  Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.

Authors:  Stephen A Brunton
Journal:  MedGenMed       Date:  2007-05-17

5.  Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM.

Authors:  C Fanelli; S Pampanelli; L Epifano; A M Rambotti; A Di Vincenzo; F Modarelli; M Ciofetta; M Lepore; B Annibale; E Torlone
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

6.  Different effects of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients.

Authors:  M Lunetta; M Di Mauro; R Le Moli
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

7.  Age-related differences in metabolic response to continuous subcutaneous insulin infusion in pre-pubertal and pubertal children with Type 1 diabetes mellitus.

Authors:  I Rabbone; A Bobbio; K Berger; M Trada; C Sacchetti; F Cerutti
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

8.  Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM.

Authors:  E Torlone; C Fanelli; A M Rambotti; G Kassi; F Modarelli; A Di Vincenzo; L Epifano; M Ciofetta; S Pampanelli; P Brunetti
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

9.  Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

Authors:  K Hermansen; P Fontaine; K K Kukolja; V Peterkova; G Leth; M A Gall
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

10.  Peripheral immune circadian variation, synchronisation and possible dysrhythmia in established type 1 diabetes.

Authors:  Craig A Beam; Eleni Beli; Clive H Wasserfall; Stephanie E Woerner; Megan T Legge; Carmella Evans-Molina; Kieran M McGrail; Ryan Silk; Maria B Grant; Mark A Atkinson; Linda A DiMeglio
Journal:  Diabetologia       Date:  2021-05-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.